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How DNA methylation inhibitors exert their anticancer effects in patients is not well understood. In the latest
issue ofCancer Cell, Tsai et al. (2012) use low-dose drug treatment to induce persistent attenuation of tumor-
igenicity by targeting tumor-initiating cells.There has been a recent surge in the
interest of epigenetics as a causal con-
tributor to cancer, as well as a basis for
alternative approaches to cancer detec-
tion, diagnosis, and therapy. In contrast
to genetic mutations and rearrange-
ments, epigenetic changes, such as
DNA methylation, do not alter the primary
DNA sequence, and are thus considered
more readily reversible. Peter Jones
discovered the first DNA methyltransfer-
ase inhibitors more than 3 decades ago
(Jones and Taylor, 1980), and showed in
this very first paper that 5-azacytidine
(5-aza-CR, AZA) and 5-Aza-20-deoxycyti-
dine (5-aza-CdR, DAC), both display a
very narrow dose range in which they
are able to inducemorphological changes
in 10T1/2 mouse fibroblasts. These drugs
were first synthesized in the 1960s, but
had yielded disappointing results in clin-
ical trials designed to escalate to the
maximum tolerated dose (MTD). Later
trials revealed that the optimal dose of
DAC was considerably lower than previ-
ously thought, with a U-shaped dose-
response curve (Issa et al., 2004; Qin
et al., 2009; Yoo and Jones, 2006). Both
drugs have now been approved by the
FDA for treatment of myelodysplastic
syndrome (MDS).
The complex dose-response relation-
ships of these drugs is attributable tomultiple competing mechanisms, which
are relevant to their efficacy, but which
have also contributed to a poor under-
standing of their mode of action. Once
incorporated into DNA, 5-azacytosine
traps DNA methyltransferases with an
irreversible covalent attachment at the
C-6 position. This has several disparate
consequences. First, the large, covalently
attached protein adduct is thought to
be cytotoxic and mutagenic (Jackson-
Grusby et al., 1997). Second, the incorpo-
rated analog acts as a sink, depleting the
cell of active DNA methyltransferases,
thus inducing secondary loss of DNA
methylation due to the lack of restoration
of DNA methylation following DNA repli-
cation. Third, once DNA methyltrans-
ferases have been fully depleted, then
incorporation of any additional drug
could yield further toxicity associated
with the analog itself, without DNA meth-
yltransferase binding. It has long been
debated whether the anticancer effects
of AZA and DAC are attributable to the
cytotoxicity of the bulky adduct or the
incorporated analog itself, to the reactiva-
tion of epigenetically silenced growth-
suppressing genes by loss of promoter
methylation, or in the case of AZA,
to incorporation of the ribonucleoside
analog into RNA. The slowly emerging
picture is that low-dose AZA or DAC caneffectively deplete DNA methyltrans-
ferases, while high doses induce cell-
cycle arrest and thus may mask replica-
tion-dependent DNA hypomethylation
(Figure 1) (Kelly et al., 2010; Qin et al.,
2009). Compounding these complex
dose-response issues, both AZA and
DAC are unstable in aqueous solution,
potentially hampering their use for poorly
perfused solid tumors. Additional impor-
tant questions remain. For example, the
clinical response of many MDS patients
to DNA methyltransferase inhibitor
therapy is delayed, yet persistent. For
some patients, blast counts continue
to decrease long after termination of
therapy (Issa and Kantarjian, 2009). Such
clinical behavior is clearly different from
that of traditional chemotherapeutic
agents, including the structurally similar
cytarabine. In the latest issue of Cancer
Cell, Baylin, Zahnow and colleagues
explore the anticancer mechanisms of
the AZA and DAC DNA methyltransferase
inhibitors that could account for this de-
layed yet persistent response (Tsai et al.,
2012).
In this report, the authors studied
the effects of these epigenetic inhibitors
at nanomolar concentrations, which ap-
proximate the in vivo concentrations at
optimal dosing, according to pharmaco-
dynamic calculations. Most of thell 10, April 6, 2012 ª2012 Elsevier Inc. 353
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Figure 1. The Emerging View in the Field Is That AZA and DAC
Effectively Demethylate DNA at Low DosesWhile Acute Cytotoxicity
Is the Primary Mechanism at High Doses
Tsai et al. show (1) how low doses of the drugs can inhibit the clonogenicity of
the tumor cell lines and primary tumor tissues via demethylation-mediated
epigenetic reprogramming in leukemia-initiating or tumor-initiating stem-like
cell subpopulations, and (2) how cytotoxicity appears to be avoided at low
doses, and bone marrow progenitors are spared, possibly because they do
not rely on aberrant hypermethylation. At higher doses (right), cytotoxicity
stalls the relatively quiescent tumor-initiating cells, impeding replication-medi-
ated demethylation. Without epigenetic reprogramming, the tumor-initiating
cells will resume growth once the drug is removed.
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ment at low doses for
3 days, followed by a subse-
quent drug-free recovery
period, and either in vitro
assays of tumorgenicity or
serial transplantation into
mice. The authors first
showed that such a short,
low-dose treatment of human
Acute Myelogenous Leuke-
mia (AML) and breast cancer
cell lines could inhibit the
subsequent in vitro colony
formation in methylcellulose
serial replating assays,
without accompanying cyto-
toxicity, cell-cycle effects, or
apoptosis. They then went
on to show that this inhibition
of clonogenicity could also be
observed for primary samples
obtained from AML patients.
This same low dose did
not affect the ability of normal
bone marrow cells to
generate progenitor colonies,
which is noteworthy, since amajor side-effect of high-dose DAC treat-
ment is myelosuppression. Transient low-
dose treatments of breast, colorectal,
and lung cancer cell lines suppressed
subsequent tumor growth when en-
grafted in untreated immunodeficient
mice. These results suggest that low-
dose DAC may be affecting a subpopula-
tion of clonogenic cells, rather than
directly inducing cytotoxicity. The authors
explored the effects of DAC on self-
renewal capacity by treating cells ob-
tained from pleural effusions of patients
with metastatic breast cancer of the
luminal type, and then serially passaging
suspension cultures of tumor spheres,
which enriches for self-renewing tumor-
initiating cells. Primary sphere formation
was dramatically inhibited by DAC, and
this effect persisted through two subse-
quent serial passages. In a more clinically
relevant test of drug efficacy, the authors
used subcutaneous treatment of prees-
tablished patient-derived tumors en-
grafted orthotopically into immunodefi-
cient mice with low-dose AZA, which
resulted in significant inhibition of tumor
growth. To further investigate whether354 Cell Stem Cell 10, April 6, 2012 ª2012 Elthese changes in phenotype were associ-
ated with the demethylating effects
of DAC, the authors showed that low-
dose treatment is sufficient to cause
genome-scale reduction of DNA methyla-
tion in gene promoters, and increased
expression of epigenetically silenced
tumor- and growth-suppressing genes,
including CDKN2A and CDKN2B. They
show that transient, low-dose treatment
with DNA methyltransferase inhibitors
results in sustained changes in major
cancer cell signaling pathways, collec-
tively reducing tumorigenicity and self-
renewal capacity.
This elegant study makes the most
convincing case to date that these
DNA methyltransferase inhibitors act to
reshape the epigenetic landscape of
self-renewing clonogenic cells, rather
than act as traditional cytotoxic agents,
at lower doses. Several unique character-
istics of these epigenetic inhibitors, such
as their delayed phenotypic effects, the
replication dependence of their action,
and their U-shaped dose-response,
warrant careful consideration in trial
design. Acute cytotoxicity induced bysevier Inc.dose escalation to MTD, or
by combination therapy with
standard cytotoxic chemo-
therapy would prevent repli-
cation-dependent demethy-
lation, while short-term
assessment of drug efficacy
could lead to false-negative
results and premature termi-
nation of treatment. On the
other hand, a thorough
understanding of the reprog-
ramming and memory effects
of epigenetic therapy can
lead to novel approaches,
such as sensitization of
cancer cells to treatment by
traditional cytotoxic agents
(Juergens et al., 2011). Epige-
netic therapy holds much
promise for targeting subpop-
ulations of self-renewing cells
that escape classical cancer
treatment. With recent ad-
vances in both drug formula-
tion and treatment regimens
andwith new stable and orally
available inhibitors on thehorizon, epigenetic drugs may become
a standard measure in clinical treatment
of a variety of cancers.
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